...
首页> 外文期刊>Degenerative Neurological and Neuromuscular Disease >New insights into the clinical evaluation of hereditary transthyretin amyloidosis patients: a single center's experience
【24h】

New insights into the clinical evaluation of hereditary transthyretin amyloidosis patients: a single center's experience

机译:遗传性运甲状腺素蛋白淀粉样变性病患者临床评估的新见解:一个中心的经验

获取原文
           

摘要

Abstract: Over the last decade, new medical treatment modalities have emerged based on increased insights into amyloid formation. With the increased possibilities for treatment of amyloidosis caused by transthyretin (TTR) amyloid deposits comes the need for diagnostic procedures for early diagnosis and better tools to follow disease progression. This is of particular importance in clinical trials evaluating the efficacy of new treatments. Until recently, the treatment of TTR amyloidosis (ATTR) was based solely on liver transplantation, a procedure that has halted disease progression in many patients. Liver transplantation has been especially effective in patients under the age of 50 years carrying the TTR V30M mutation, whereas the outcome of the procedure has been variable for others, particularly elderly male patients and those carrying a non-V30M mutation. This review concentrates on new insights derived from our center's experience with liver transplantation, how to implement this experience in evaluation of new treatment modalities for ATTR, and how to facilitate early diagnosis of neuropathy with easily available diagnostic tools. Attention has focused on manifestations of the disease that involve the heart and the peripheral nervous system; change in peripheral nerve function has been the primary endpoint in two controlled clinical trials, one finished and one ongoing. New insights into the amyloid formation process and the lessons learned from liver transplantation give the opportunity to design potentially effective treatment modalities for ATTR. It appears reasonable to suspect that a combination of different treatment modalities may be required to treat the disease, and that different treatment regimes will be designed according to the phenotype of the disease. For the patients and their relatives there is now a solid foundation for optimism, with prospects of several effective medical treatment possibilities within the coming decade.
机译:摘要:在过去的十年中,基于对淀粉样蛋白形成的深入了解,出现了新的医学治疗方法。随着运甲状腺素蛋白(TTR)引起的淀粉样变性的治疗可能性的增加,淀粉样沉积物的需求是需要早期诊断的诊断程序和更好的工具来追踪疾病进展。这在评估新疗法功效的临床试验中尤为重要。直到最近,TTR淀粉样变性病(ATTR)的治疗仍完全基于肝移植,该方法已停止了许多患者的疾病进展。肝移植在携带TTR V30M突变的50岁以下患者中尤其有效,而该过程的结果对于其他人(尤其是老年男性患者和携带非V30M突变的患者)却有所不同。这篇综述着重于从我们中心在肝移植方面的经验得出的新见解,如何在评估ATTR的新治疗方式时运用这种经验,以及如何利用易于获得的诊断工具促进神经病的早期诊断。注意力集中在涉及心脏和周围神经系统的疾病表现上。周围神经功能的变化一直是两项对照临床试验的主要终点,一项完成,一项正在进行。对淀粉样蛋白形成过程的新见解以及从肝移植中吸取的教训使人们有机会为ATTR设计潜在有效的治疗方式。似乎合理地怀疑可能需要组合使用不同的治疗方式来治疗该疾病,并且将根据该疾病的表型设计不同的治疗方案。对于患者及其亲属而言,现在已经为乐观打下了坚实的基础,并且在未来十年内有望有几种有效的治疗方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号